Effect of Low-Dose Steroids as an Adjunct to Anti-Tubercular Therapy on Lymph Node Regression in Tuberculous Lymphadenitis: A Randomized Controlled Trial

Fahad Javed Awan; Shahzed Ahmed Satti; Amna Butt; Muhammad Uneeb Ullah; Hafiz Asad Saeed; Farhan Zaid; Muhammad Hammad

doi:10.51253/pafmj.v76iSUPPL-2.11683

Authors

Fahad Javed Awan Department of Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Shahzed Ahmed Satti Department of Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Amna Butt Department of Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Muhammad Uneeb Ullah Department of Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Hafiz Asad Saeed Department of Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Farhan Zaid Department of Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Muhammad Hammad Department of Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-2.11683

Keywords:

ATT, Lymph node, Prednisone, Steroids, Tuberculosis, Tuberculous lymphadenitis.

Abstract

Objective: To study the effect of low-dose steroids in addition to anti-tubercular treatment on the regression of Lymph node size in patients with Tuberculous Lymphadenitis

Study Design: Randomised Control Trial (NCT06236152).

Place and Duration of Study: Department of Medicine, Pak Emirates Military Hospital, Rawalpindi, Pakistan, from Sep 22 to Dec 23.

Methodology: Patients with Tuberculous Lymphadenitis who presented to PEMH Rawalpindi were randomized into two groups of 55 patients each. Group-A was given low-dose steroids with ATT, and Group-B was given a placebo with ATT. Lymph node (LN) size was measured at start of treatment and followed up after 2 months and end of treatment. LN size regression was noted and compared in both groups along with incidence of side effects of steroids and ATT drugs.

Results: The largest reported lymph node or the matted nodal mass size, before the start of the treatment was 4.09 ± 1.41 cm and 3.98 ± 1.26 cm in Group-A and Group-B respectively. In Group-A, 20 (36.4%) patients achieved regression in the lymph node size by 50% at the end of consolidation phase, whereas in Group-B 18 (32.7%) achieved the same (p=0.430). By the end of 6 months of treatment, 38 (69.1%) patients of Group-A had achieved regression in the lymph node size of more than 50% while 35 (63.6%) of the Group-B patients had achieved the same (p=0.235).

Conclusion: A lower dose of prednisolone was of limited benefit and ineffective for regression of lymph node size as compared to alone standard ATT.

Downloads

Download data is not yet available.

References

1. Villar-Hernández R, Ghodousi A, Konstantynovska O, Duarte R, Lange C, Raviglione M. Tuberculosis: current challenges and beyond. Breathe 2023; 19(1): 220166.

https://doi.org/10.1183/20734735.0166-2022

2. Migliori GB, Wu SJ, Matteelli A, Zenner D, Goletti D, Ahmedov S, et al. Clinical standards for the diagnosis, treatment and prevention of TB infection. int j tuberc lung dis 2022; 26(3): 190–205. https://doi.org/10.5588/ijtld.21.0753

3. Bakshi SS. Tubercular lymphadenitis. The American Journal of the Medical Sciences. 2022; 364(6): e92–e93.

https://doi.org/10.1016/j.amjms.2022.07.016

4. Öztomurcuk D, Terzi Ö, Ondokuz M, Demirci C et al. Investigation of Granulomatous Inflammations in Terms of Tuberculosis Diagnosis: A 5-Year Multi-center Laboratory Study. Turk Thorac J 2022; 23(1): 11–16.

https://doi.org/10.5152/TurkThoracJ.2022.20314

5. Kontsevaya I, Cabibbe AM, Cirillo DM, DiNardo AR, Frahm N, Gillespie SH, et al. Update on the diagnosis of tuberculosis. Clin Microbiol Infect 2023; S1198743X23003403.

https://doi.org/10.1016/j.cmi.2023.07.014

6. Donovan J, Khanh TDH, Thwaites GE, Geskus RB, ACT HIV investigators. A statistical analysis plan for the Adjunctive Corticosteroids for Tuberculous meningitis in HIV-positive adults (ACT HIV) clinical trial. Wellcome Open Res 2021; 6: 280.

https://doi.org/10.1056/NEJMoa2216218

7. Lekhbal A, Chaker K, Halily S, Abada RL, Rouadi S, Roubal M, et al. Treatment of cervical lymph node tuberculosis: When surgery should be performed? A retrospective cohort study. Ann Med Surg 2020; 55: 159–163.

https://doi.org/10.1016/j.amsu.2020.05.006

8. Bagcchi S. WHO's Global Tuberculosis Report 2022. Lancet Microbe 2023; 4(1): e20.

https://doi:10.1016/S2666-5247(22)00359-7

9. Kazi GN, Eman K ul, Mohamud KB, Quadir A, Shah SK, Haq ZU. Tuberculosis control in Pakistan: A decade (2011-2020) in review. Pak J Public Health 2022; 12(1): 17–22.

https://doi.org/10.32413/pjph.v12i1.955

10. Abbas S, Kermode M, Kane S. Strengthening the response to drug-resistant TB in Pakistan: a practice theory-informed approach. Public Health Action 2020; 10(4): 147–156.

https://doi.org/10.5588/pha.20.0030

11. Bunkar ML, Agnihotri SP, Gupta PR, Arya S. Add-on prednisolone in the management of cervical lymph node tuberculosis. Indian J Tuberc 2016; 63(2): 96–99.

https://doi.org/10.1016/j.ijtb.2015.05.002

12. Majeed MM, Bukhari MH. Evaluation for Granulomatous Inflammation on Fine Needle Aspiration Cytology Using Special Stains. Patholog Res Int 2011; 2011: 851524.

https://doi.org/10.4061/2011/851524

13. Munir F, Ahmad S, Ullah S, Wang YP. Understanding housing inequalities in urban Pakistan: An intersectionality perspective of ethnicity, income and education. J Race, Ethnicity and the City 2022; 3(1): 1–22.

https://doi.org/10.1080/26884674.2021.1986442

14. Sharmin A, Hossain A, Islam N, Sarker ZH, Hossain SS, Khan MA. Outcome of lymph node tuberculosis management with conventional treatment with and without prednisolone. Trop Doct 2021; 51(3): 288–291.

https://doi.org/10.1177/0049475520984745

15. Chahed H, Hachicha H, Berriche A, Abdelmalek R, Mediouni A, Kilani B, et al. Paradoxical reaction associated with cervical lymph node tuberculosis: predictive factors and therapeutic management. Int J Infect Dis 2017; 54: 4–7.

https://doi.org/10.1016/j.ijid.2016.10.025

16. Amin A, Vartanian A, Yegiazaryan A, Al-Kassir AL, Venketaraman V. Review of the Effectiveness of Various Adjuvant Therapies in Treating Mycobacterium tuberculosis. Infect Dis Rep 2021; 13(3): 821–834.

https://doi.org/10.3390/idr13030074

17. Djochie RDA, Anto BP, Opare-Addo MNA. Determinants of adverse reactions to first-line antitubercular medicines: a prospective cohort study. J Pharm Policy Pract 2023; 16(1): 70.

https://doi.org/10.1186/s40545-023-00577-6

18. Sankar KNH, Roch K, Jom D, Palappallil DS, Panattil P, Sankaranarayanan RK. Adverse drug reaction profile of daily regimen antituberculosis treatment. Perspect Clin Res 2022; 13(4): 194–198.

https://doi.org/10.4103/picr.PICR_279_20

19. Schutz C, Davis AG, Sossen B, Lai RPJ, Ntsekhe M, Harley YX, et al. Corticosteroids as an adjunct to tuberculosis therapy. Expert Rev Respir Med 2018; 12(10): 881–891.

https://doi.org/10.1080/17476348.2018.1515628

20. Gupta P. Role of Add-on Prednisolone in the Management of Peripheral Lymph Node Tuberculosis. J Infectiology 2018; 1(2): 4–6.

https://doi.org/10.29245/2689-9981/2018/2.1115